This trial is evaluating an oral cancer drug (asciminib) in patients with newly diagnosed chronic phase myeloid leukaemia.
This trial is treating patients with chronic myeloid leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Australasian Leukaemia and Lymphoma Group (ALLG) single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)
All eligible patients will receive 40mg of oral asciminib twice a day for up to five years.
Recruiting Hospitals Read More